61 citations
,
August 2022 in “Journal of Controlled Release” Dissolving microneedles show promise for delivering medication through the skin but face challenges like manufacturing complexity and regulatory hurdles.
2 citations
,
July 2023 in “Phytotherapy Research” Serenoa repens is mostly safe but has some risks, especially at high doses or when used with other products for over two weeks.
6 citations
,
July 2019 in “Journal of Dermatological Treatment” LLLT devices for hair loss need more research to define proper guidelines.
5 citations
,
July 2019 in “Journal of Cutaneous Medicine and Surgery” Isotretinoin may cause hair loss, especially in women and young adults.
2 citations
,
August 2013 in “The Lancet. Diabetes & endocrinology” The FDA rejected a testosterone drug again due to safety concerns.
July 2020 in “Journal of Investigative Dermatology” FDA-cleared devices often fail to produce high-quality platelet-rich plasma consistently.
April 2020 in “Online journal of complementary & alternative medicine” Some medications can help increase sexual desire and function in women.
The FDA did not approve a testosterone drug because of safety concerns.
September 2015 in “Korean Journal of Clinical Pharmacy” Dutasteride is highly effective for hair loss treatment in Korea, with more side effects than finasteride.
1 citations
,
September 2022 in “Nepal journal of dermatology, venereology & leprology” Apremilast shows promise for several skin conditions but needs more research.
August 2021 in “Letters in Applied NanoBioScience” Pranlukast and mirabegron may work as new diabetes drugs.
A new acne cream effectively reduced acne in trials and awaits FDA approval.
11 citations
,
July 2020 in “Scientific Reports” Statins may be linked to reproductive organ conditions, and their risks should be monitored.
May 2016 in “The Journal of Sexual Medicine” 6 citations
,
September 2021 in “Journal of the American Academy of Dermatology” PRP treatments for hair loss need standard protocols to be reliable.
3 citations
,
July 2022 in “BMC chemistry”
Finasteride and testosterone are the drugs most linked to male infertility, but many other potential drugs may be under-reported.
Some drugs may increase the risk of obstructive sleep apnea, while others like certain biologics might decrease it.
May 2016 in “The Journal of Sexual Medicine” Younger people (median age 35) experience more PFS-like symptoms with 1mg finasteride; more research needed.
3 citations
,
September 2020 in “Molecular Brain” The anti-viral drug Elvitegravir may protect brain cells from damage related to neurodegenerative diseases.
January 2024 in “Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy” New, eco-friendly methods accurately measure TDF and FNS in a new urologic medication.
January 2023 in “RSC Advances”
1 citations
,
April 2018 in “Sleep” Finasteride increases risk of sleep apnea and insomnia.
2 citations
,
May 2022 in “International Journal of Impotence Research”
October 2021 in “European urology open science”
September 2018 in “Journal of The American Academy of Dermatology”
110 citations
,
August 2016 in “Drugs” Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.
30 citations
,
January 2000 in “Dermatologic Clinics” Finasteride and minoxidil are effective FDA-approved treatments for androgenetic alopecia.
20 citations
,
May 2015 in “Regenerative Medicine” The document warns against US clinics selling untested stem cell treatments without FDA approval.
16 citations
,
September 2019 in “International Journal of Women's Dermatology” The new FDA labeling rules provide more detailed drug safety information for pregnant and breastfeeding women, but more data is needed on the risks of many dermatologic drugs.